• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·China·Healthcare·002030.SZ
Share

Daan Gene Co., Ltd. Stocks

CN¥ 6.97Last Updated 26.05.2026

Issuer Rating

4/7
Performance

Modest

Risk

Limited

Recommendation

Hold

Market Cap

CN¥ 1.41B

CN¥ 6.97
Key Takeaways

Risk factor

Good trading liquidity

Data is available to registered users only
Data is available to registered users only

Profitability factor

Very poor margins and returns

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Daan Gene Co., Ltd. researches and develops, manufactures, and sells clinical test reagents and instruments. The company offers fluorescence quantitative PCR products, time resolution series products, enzyme-linked immunoassay products, instrument products, and scientific research service products. It also provides medical examination, and health consultation and management services, such as genetic susceptibility gene testing, tumor marker testing, cervical cancer screening, routine physical examination, and other health services. The company was formerly known as Da An Gene Co., Ltd. of Sun Yat-Sen University. The company was founded in 2001 and is headquartered in Guangzhou, the People's Republic of China.

Company Valuation

Overvalued
2/7

Considering past and projected metrics, the stock is 'expensive' compared to its peers. Specifically, the stock is 'expensive' on P/E, overvalued on EV/EBITDA, overpriced

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

28.05.2026 19:22

'It's crazy': chipmaker stocks break dot-com era records. Will the rally continue?

28.05.2026 18:56

US stocks retreated from highs amid accelerating inflation and escalating war

28.05.2026 17:55

Consumer spending inflation in the US has reached a three-year high

28.05.2026 17:21

The Russian ruble has strengthened to a three-year high. What is helping it?

28.05.2026 16:55

Micro-cap Astrotech more than quintuples in a day amid strategic Moon initiative

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn
  • X (Twitter)
  • LinkedIn
Oninvest© 2026